SCHEMBL3407914

SCHEMBL3407914

CN(CCCC1(c2ccc(Cl)cc2)OCc2cc(-c3ccccc3C(F)(F)F)ccc21)CC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.48
BCHE P06276 3/20 0.47
SLC6A4 P31645 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL468501 0.90 BCHE (0.52) ACHEBCHESLC6A4
SCHEMBL30130502 0.90 BCHE (0.52) ACHEBCHESLC6A4
SCHEMBL7079030 0.89 ACHE (0.48) ACHEBCHESLC6A4
SCHEMBL3408176 0.87 SLC6A4 (0.56) ACHESLC6A4
SCHEMBL30130509 0.87 SLC6A4 (0.56) ACHESLC6A4
SCHEMBL468409 0.86 SLC6A4 (0.52) ACHESLC6A4
SCHEMBL30130512 0.86 SLC6A4 (0.52) ACHESLC6A4
SCHEMBL3406535 0.86 SLC6A4 (0.52) ACHEBCHESLC6A4
SCHEMBL30130482 0.86 SLC6A4 (0.52) ACHEBCHESLC6A4
SCHEMBL3407874 0.85 ACHE (0.49) ACHEBCHESLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223857-A1 Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression H. LUNDBECK A/S (DK) 2006-10-05 US claimed
EP-1301502-B1 COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS LUNDBECK & CO AS H (DK) 2005-05-18 EP claimed
US-11529342-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2022-12-20 US disclosed
US-20190151301-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2019-05-23 US disclosed
EP-3006024-B1 BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) 2019-03-20 EP disclosed
US-10149845-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2018-12-11 US disclosed
US-10039730-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2018-08-07 US disclosed
US-20170189358-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2017-07-06 US disclosed
US-20170181989-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2017-06-29 US disclosed
US-9675604-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2017-06-13 US disclosed
US-9649304-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2017-05-16 US disclosed
US-20150099015-A1 Sorbic and Benzoic Acid and Derivatives Thereof Enhance the Activity of a Neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER 2015-04-09 US disclosed
US-20100189818-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2010-07-29 US disclosed
US-20060223857-A1 Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression H. LUNDBECK A/S (DK) 2006-10-05 US disclosed
WO-2006000222-A2 THE COMBINATION OF AN ANTIPSYCHOTIC AND A GLYCINE TRANSPORTER TYPE I INHIBITOR FOR THE TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2006-01-05 WO disclosed
US-6921774-B2 Compounds and their use as glycine transport inhibitors H. LUNDBECK A/S (DK) 2005-07-26 US disclosed
EP-1301502-B1 COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS LUNDBECK & CO AS H (DK) 2005-05-18 EP disclosed
US-20030181445-A1 Novel compounds and their use as glycine transport inhibitors H. LUNDBECK A/S (DK) 2003-09-25 US disclosed
EP-1301502-A1 NOVEL COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS H. Lundbeck A/S (DK) 2003-04-16 EP disclosed
WO-2002008216-A1 NOVEL COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS H. LUNDBECK A/S (DK) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181445-A1 Novel compounds and their use as glycine transport inhibitors SLC1A5, SLC7A1, SLC7A11 ACHE 4176/4885BCHE 2384/4885SLC6A4 75/4885
US-20060223857-A1 Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression SLC6A4, SLC6A7, SLC6A5 ACHE 3392/4885BCHE 2957/4885SLC6A4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.